Amid a month of skyrocketing stock prices and unprecedented social media buzz, Hims & Hers is expanding its territory into at-home blood testing and diagnostics.Hims has acquired at-home lab testing facility Trybe Labs, the telehealth company said Wednesday. Using at-home blood draws, Hims will now offer over 70 at-home diagnostics tests, ranging from heart health to certain cancer detection tests.All these can be arranged through the app, without a doctors visit.At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect, Dr. Patrick Carroll, Hims & Hers chief medical officer, told CNBC.Trybe Labs is based in New Jersey, and Hims & Hers will use these labs to process blood tests at low-cost for Hims & Hers members, using state-of-the-art diagnostic equipment, according to its webpage.Pricing information for these tests will come out within the next year, according to the company.Hims & Hers stock was up 23% during midday trading on Wednesday, following the news of the acquisition.By offering at-home testing, Hims & Hers now puts itself in competition with industry juggernauts like Labcorp and Quest Diagnostics. Shares of Hims have jumped 230% in the last three months, while Labcorps and Quests have grown only by 4 and 6%, respectively.The move comes during what has seemed like a month of Hims & Hers domination. The telehealth company, which vows to let its members skip the awkward doctors visits, recently entered the public consciousness with a viral and controversial Super Bowl ad.The ad criticized the pharmaceutical industry while promoting itself as a cheaper alternative. Within the ad, a spokeswoman says: There are medicines that work, but theyre priced for profits, not patients.After the ad aired, Hims & Hers saw a 650% increase in website traffic and an 11% increase in stock price.